MedKoo Cat#: 414003 | Name: Edonerpic Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Edonerpic Free Base is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

Chemical Structure

Edonerpic Free Base
Edonerpic Free Base
CAS#519187-23-6 (free base)

Theoretical Analysis

MedKoo Cat#: 414003

Name: Edonerpic Free Base

CAS#: 519187-23-6 (free base)

Chemical Formula: C16H21NO2S

Exact Mass: 291.1293

Molecular Weight: 291.41

Elemental Analysis: C, 65.95; H, 7.26; N, 4.81; O, 10.98; S, 11.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Edonerpic Free Base; T817; T 817; T-817
IUPAC/Chemical Name
1-(3-(2-(Benzo(b)thiophen-5-yl)ethoxy)propyl)azetidin-3-ol
InChi Key
HQNACSFBDBYLJP-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H21NO2S/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2
SMILES Code
OC1CN(CCCOCCC2=CC=C3C(C=CS3)=C2)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 291.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moutal A, Shan Z, Miranda VG, François-Moutal L, Madura CL, Khanna M, Khanna R. Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels (Austin). 2019 Dec;13(1):498-504. doi: 10.1080/19336950.2019.1684608. PMID: 31680630; PMCID: PMC6833970. 2: Pines AR, Sattur MG, Abi-Aad KR, Bendok BR. Edonerpic Maleate: A Promising Pharmacological Agent for Stroke Recovery. Neurosurgery. 2019 Jan 1;84(1):E3-E4. doi: 10.1093/neuros/nyy397. PMID: 30551191. 3: Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer’s Disease Cooperative Study TCAD Study Group. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019 Nov 1;76(11):1330-1339. doi: 10.1001/jamaneurol.2019.1868. PMID: 31282954; PMCID: PMC6618817. 4: Abe H, Jitsuki S, Nakajima W, Murata Y, Jitsuki-Takahashi A, Katsuno Y, Tada H, Sano A, Suyama K, Mochizuki N, Komori T, Masuyama H, Okuda T, Goshima Y, Higo N, Takahashi T. CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage. Science. 2018 Apr 6;360(6384):50-57. doi: 10.1126/science.aao2300. PMID: 29622647. 5: Takahashi T. Novel synaptic plasticity enhancer drug to augment functional recovery with rehabilitation. Curr Opin Neurol. 2019 Dec;32(6):822-827. doi: 10.1097/WCO.0000000000000748. PMID: 31567431; PMCID: PMC6855342. 6: Khanna R, Moutal A, Perez-Miller S, Chefdeville A, Boinon L, Patek M. Druggability of CRMP2 for Neurodegenerative Diseases. ACS Chem Neurosci. 2020 Sep 2;11(17):2492-2505. doi: 10.1021/acschemneuro.0c00307. Epub 2020 Aug 4. PMID: 32693579.